However, while selective blockade of pro-inflammatory cytokines is one of the most effective strategies to down-regulate mucosal inflammation in IBD (8), Phase I clinical trials using strategies to neutralize either IL-1 or IL-18 have failed to show significant efficacy in treating patients with UC and CD, respectively. Here, IL1A is linked to inflammatory bowel disease.